NeOnc Targets 2026 Pivotal Trials as Roth Initiates Coverage

Event summary

Roth Capital initiated coverage of NeOnc Technologies, highlighting potential 2026 pivotal trial starts for NEO100.
NeOnc reported 48.9% six-month progression-free survival in Phase 2a trial for NEO100, exceeding 20% benchmark.
Company raised $15M in September via registered direct offering at $4.20 per share.
NEO212 program advanced with FDA feedback on manufacturing and Phase 1 dose establishment.

The big picture

NeOnc's transition from early-stage developer to potential commercial player in CNS oncology comes as Roth's coverage highlights near-term catalysts. The $15M raise and executive share purchases signal confidence in NEO100's regulatory path, while NEO212's progress positions the company to address multiple high-unmet-need indications. Success hinges on maintaining clinical momentum through 2026 pivotal trials.

What we're watching

Regulatory Timing: Whether FDA Type B meeting in October will confirm 2026 pivotal trial timeline for NEO100.
Capital Efficiency: How $15M raise will support NEO100/NEO212 development through potential approvals.
Clinical Momentum: Pace of NEO212 Phase 2 initiation following manufacturing feedback and dose establishment.